CL2020000684A1 - Composiciones, usos y procedimientos para el tratamiento de la infertilidad y la subfertilidad. - Google Patents

Composiciones, usos y procedimientos para el tratamiento de la infertilidad y la subfertilidad.

Info

Publication number
CL2020000684A1
CL2020000684A1 CL2020000684A CL2020000684A CL2020000684A1 CL 2020000684 A1 CL2020000684 A1 CL 2020000684A1 CL 2020000684 A CL2020000684 A CL 2020000684A CL 2020000684 A CL2020000684 A CL 2020000684A CL 2020000684 A1 CL2020000684 A1 CL 2020000684A1
Authority
CL
Chile
Prior art keywords
treatment
infertility
subfertility
compositions
procedures
Prior art date
Application number
CL2020000684A
Other languages
English (en)
Inventor
Unfer Vittorio
Original Assignee
Lo Li Pharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lo Li Pharma Srl filed Critical Lo Li Pharma Srl
Publication of CL2020000684A1 publication Critical patent/CL2020000684A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE, ENTRE OTRAS COSAS, A COMPOSICIONES QUE SON ADECUADAS PARA EL TRATAMIENTO DE LA INFERTILIDAD O LA SUBFERTILIDAD, EN PARTICULAR LA INFERTILIDAD O SUBFERTILIDAD CAUSADA POR SÍNDROME DEL OVARIO POLIQUÍSTICO (SOPQ) O ANOVULACIÓN, O QUE SON ADECUADAS PARA EL TRATAMIENTO DEL SOPQ O DE LA ANOVULACIÓN POR SÍ MISMOS.
CL2020000684A 2017-09-19 2020-03-16 Composiciones, usos y procedimientos para el tratamiento de la infertilidad y la subfertilidad. CL2020000684A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000104446A IT201700104446A1 (it) 2017-09-19 2017-09-19 Compositions, uses and methods for treatment of infertility and subfertility

Publications (1)

Publication Number Publication Date
CL2020000684A1 true CL2020000684A1 (es) 2020-08-21

Family

ID=60991464

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000684A CL2020000684A1 (es) 2017-09-19 2020-03-16 Composiciones, usos y procedimientos para el tratamiento de la infertilidad y la subfertilidad.

Country Status (17)

Country Link
US (2) US11364282B2 (es)
EP (1) EP3684372A1 (es)
KR (1) KR102468673B1 (es)
AR (1) AR112700A1 (es)
BR (1) BR112020005537A2 (es)
CA (1) CA3075582A1 (es)
CL (1) CL2020000684A1 (es)
CO (1) CO2020002658A2 (es)
EA (1) EA202090790A1 (es)
IT (1) IT201700104446A1 (es)
JO (1) JOP20200065A1 (es)
MA (1) MA50163A (es)
MX (1) MX2020002914A (es)
SG (1) SG11202001756YA (es)
UY (1) UY37885A (es)
WO (1) WO2019057709A1 (es)
ZA (1) ZA202002366B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053685A1 (en) * 2019-09-20 2021-03-25 Ramesh Patodia A novel nutraceutical formulation for polycystic ovary syndrome (pcos)
WO2024170665A1 (en) * 2023-02-17 2024-08-22 Lo.Li. Pharma S.R.L. Composition for the use in the treatment of polycystic ovary syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039967A (en) 1997-04-03 2000-03-21 Point Biomedical Corporation Intravesical drug delivery system
EP1228707A1 (en) 2001-02-01 2002-08-07 Campina Melkunie B.V. Use of alpha-lactalbumin as prebiotic agent
GB0205347D0 (en) * 2002-03-07 2002-04-24 Svanborg Catharina Biologically active complex
ITRM20070341A1 (it) * 2007-06-20 2008-12-21 Lo Li Pharma Srl Formulazione integrativa inofolic finalizzata al controllo dell'induzione dell'ovulazione in programmi di procreazione medicalmente assistita
ITFI20110252A1 (it) * 2011-11-22 2013-05-23 Lo Li Pharma Srl Composizione farmaceutica comprendente myo-inositolo e d-chiro-inositolo.
MX2012010488A (es) * 2012-09-11 2014-03-26 Nucitec Sa De Cv Formula infantil para el optimo crecimiento, proteccion gastrointestinal y proteccion inmunologica de infantes.
US20140294795A1 (en) * 2013-03-28 2014-10-02 Houn Simon Hsia Nutritional Composition
WO2016020495A1 (en) * 2014-08-08 2016-02-11 Nestec S.A. Myo-inositol and one or more probiotic and use thereof
CN104365997A (zh) * 2014-12-14 2015-02-25 河南联合英伟饲料有限公司 一种家畜幼仔奶粉饲料

Also Published As

Publication number Publication date
EA202090790A1 (ru) 2020-06-17
KR20200092939A (ko) 2020-08-04
CO2020002658A2 (es) 2020-05-15
US20200215165A1 (en) 2020-07-09
IT201700104446A1 (it) 2019-03-19
CA3075582A1 (en) 2019-03-28
BR112020005537A2 (pt) 2020-10-06
EP3684372A1 (en) 2020-07-29
MA50163A (fr) 2020-07-29
AR112700A1 (es) 2019-11-27
ZA202002366B (en) 2024-09-25
JOP20200065A1 (ar) 2020-03-17
US20220062388A1 (en) 2022-03-03
UY37885A (es) 2018-11-30
WO2019057709A1 (en) 2019-03-28
MX2020002914A (es) 2020-08-17
KR102468673B1 (ko) 2022-11-17
US11364282B2 (en) 2022-06-21
SG11202001756YA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2017003404A1 (es) Compuestos antibacterianos
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2018002671A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
CL2018001226A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
DOP2018000219A (es) Anticuerpos anti-factor bb del complemento y usos de estos
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
PE20180187A1 (es) Formulacion de combinacion de tesofensina y betabloqueante
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
CL2020000684A1 (es) Composiciones, usos y procedimientos para el tratamiento de la infertilidad y la subfertilidad.